HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrew McConaghie

Senior Writer

Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.

He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.

Set Alert for Articles By Andrew McConaghie

Latest From Andrew McConaghie

BioMarin’s Momentum Grows With Twin Blockbuster Plans

The frontrunner in hemophilia A gene therapy has been hit by data doubts, but this and achondroplasia drug could deliver in 2020.

Clinical Trials FDA

Staying Diversified, Bayer Sees Opportunities In Digital Innovation

Despite its Monsanto woes, Bayer is sticking with its diversified portfolio, and is branching out into patient-facing digital health services.

Commercial Digital Health

Clear Path For AstraZeneca’s Roxadustat After Reassuring Safety Data

Strong results in non-dialysis patients are a particular boost for AZ and its partner, Fibrogen.

Clinical Trials Research & Development

NHS England Hails Biggest CAR-T Uptake In Europe

Pharma must “speak the same language” as the National Health Service for “transactable” negotiations.

Europe United Kingdom

UK Biotech Ervaxx Launches With Focus On ‘Dark Antigens’

Melanoma is first target for company developing cancer vaccines and T-cell receptor immunotherapies.

United Kingdom Research & Development

ASH Preview: J&J And Legend’s CAR-T Takes Center Stage

While bluebird bio, Celgene and GSK prepare to file, it’s time to shine for another myeloma contender.

Clinical Trials ImmunoOncology
See All
UsernamePublicRestriction

Register